Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis

Abstract

Diflunisal was tolerated well by most hereditary ATTR amyloidosis patients, although renal function and blood cell counts must be carefully monitored. Clinical effects of diflunisal were sustained after 2 years of treatment.